Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.